Lysando Innovations Lab GmbH

Business Strategies

Recombinant, selective acting (Artilysin®) antimicrobial proteins engineered and developed by ISO 13485 certified Lysando Innovations Lab GmbH to efficiently combat bacterial pathogens. The resulting Artilysin^® platform finds application in almost all fields that are under bacterial attack.

Artilysin^®

- finds particular application combating antibiotic resistant bacteria

- is effective against gram negative bacteria (e.g. Acinetobacter, Salmonella, EHEC, Pseudomonas)

- is effective against gram positive bacteria (e.g. Staphylococcus, Streptococcus)

Core Technologies and Services

Based on the Artilysin^® platform, applicable Artilysin^® is developed according to customer specifications. Artilysin^® acts selectively so that pathogenic target bacteria are foremost eliminated and the microbiome remains intact. The bacteria are lysed via a mechanical, physical mechanism within seconds. Artilysin^® is environmentally-friendly, is rapidly biologically degraded and therefore dose not accumulate in the environment. Artilysin^® compared to antibiotics is significantly more stable to the development of resistance.

Patent, Licenses, Co-operations

Lysando Innovations Lab GmbH distinguishes itself with goal-directed and expeditious work, is punctual and works closely with customers. Lysando Innovations Lab GmbH has much experience in working with large concerns and medium-sized companies. The Artilysin^® platform is protected by a broad patent portfolio.

Distribution

Please contact our office directly: Markus Matuschka v. Greiffenclau  markus@lysando.com